These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16490026)

  • 21. [Initial experiences with prostaglandin E1 and PGE1 prepared injections].
    Mattarelli G; Leibundgut B
    Helv Chir Acta; 1991 Sep; 58(3):335-7. PubMed ID: 1769856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis.
    Elhanbly S; Schoor R; Elmogy M; Ross L; Hegazy A; Niederberger C
    J Urol; 2002 Jan; 167(1):192-6. PubMed ID: 11743303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
    Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
    Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
    Buvat J; Lemaire A; Herbaut-Buvat M
    Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erection hardness score for the evaluation of erectile dysfunction: further psychometric assessment in patients treated by intracavernous prostaglandins injections after radical prostatectomy.
    Parisot J; Yiou R; Salomon L; de la Taille A; Lingombet O; Audureau E
    J Sex Med; 2014 Aug; 11(8):2109-18. PubMed ID: 24840184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracavernous injection as an option for aging men with erectile dysfunction.
    Wespes E
    Aging Male; 2002 Sep; 5(3):177-80. PubMed ID: 12471778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Office treatment: intracavernous injections of prostaglandin E1 (PG E1) and improvement of spontaneous erections.
    Beretta G; Marzotto M; Zanollo A; Re B
    Acta Eur Fertil; 1991; 22(4):221-3. PubMed ID: 1844326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Transurethral alprostadil (MUSE) in erectile dysfunction].
    Comeri G; Gianneo E; Nespoli R
    Arch Ital Urol Androl; 1999 Sep; 71(4):249-51. PubMed ID: 10592541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Group B streptococcal septicemia following intracavernous injection therapy for erectile dysfunction in diabetes.
    Nalesnik JG; Jones L; Kraus SR
    J Urol; 2004 Jul; 172(1):151-2. PubMed ID: 15201758
    [No Abstract]   [Full Text] [Related]  

  • 33. MUSE therapy: preliminary clinical observations.
    Werthman P; Rajfer J
    Urology; 1997 Nov; 50(5):809-11. PubMed ID: 9372900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus.
    Israilov S; Shmuely J; Niv E; Engelstein D; Livne P; Boniel J
    Int J Impot Res; 2005; 17(5):431-6. PubMed ID: 15889124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 36. The incidence and management of priapism in Western Australia: a 16 year audit.
    Earle CM; Stuckey BG; Ching HL; Wisniewski ZS
    Int J Impot Res; 2003 Aug; 15(4):272-6. PubMed ID: 12934055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic effects of transurethral alprostadil measured by color duplex ultrasonography in men with erectile dysfunction.
    Tam PY; Keller T; Poppiti R; Gesundheit N; Padma-Nathan H
    J Urol; 1998 Oct; 160(4):1321-4. PubMed ID: 9751345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does prostaglandin E1 therapy modify the intracavernous musculature?
    Wespes E; Sattar AA; Noël JC; Schulman CC
    J Urol; 2000 Feb; 163(2):464-6. PubMed ID: 10647655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prostaglandin E1 in the diagnosis and therapy of erectile disorders].
    Loran OB; Segal AS; Shcheplev PA
    Urol Nefrol (Mosk); 1995; (4):35-8. PubMed ID: 7571200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does compression of the base of the penis improve the efficacy of intracavernosal injection of prostaglandin E1 for impotence? A randomized controlled study.
    el-Saleh JC; Keogh EJ; Chew KK; Earle CM; Lee JL; Wearmouth JW
    Int J Impot Res; 1995 Mar; 7(1):23-31. PubMed ID: 7670590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.